semaglutide cardiovascular outcomes trial align more closely with attained dose than achieved weight loss Semaglutide (SUSTAIN and PIONEER) reduces

Non-surgical fat reduction methods, such as injectable treatments, have gained popularity due to their minimal downtime and potential for visible results

doi: 10.1016/j.soard.2019.06.022 16 JerlhagE.EgeciogluE.DicksonS

Elevated LOXL2 expression in estrogen receptor-negative breast tumors is strongly associated with unfavorable outcomes, including poor prognosis, decreased overall survival, and reduced metastasis-free survival, suggesting that LOXL2 could serve as a valuable prognostic marker for metastasis in breast cancer cases

Unlike traditional fillers, they dont fill space instantly

The choice often depends on whether the primary concern is local GI healing versus systemic chronic inflammation affecting multiple systems